Pharming Group   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Leiden Netherlands (1988)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2003
NCT00261053
First Marketed Drug
2014
conestat alfa (Ruconest)
First NDA Approval
2023
Leniolisib (Joenja)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

COO Pharming | PHARMING | Pharming Americas BV | Pharming Group N.V. | Pharming Technologies BV | Pharming Technologies B.V.

Active Ingredients

Marketed Drugs (2)

conestat alfa (Ruconest) (2014)

Leniolisib (Joenja) (2023 NDA)

Drugs in Phase 3 Trials (2)

C1 Esterase Inhibitor (Human) (Cinryze) (10 trials)

Leniolisib (Joenja) (2 trials)

Drugs in Phase 2 Trials (4)

Key: Pharming Group (3) Acquired (1)

conestat alfa (Ruconest) (5 trials)

immune globulin (human) (Gamastan) (1 trial)

mannitol (Osmitrol) (1 trial)

sodium chloride (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Angioedema (Phase 3)

Angioedemas, Hereditary (Phase 3)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Delayed Graft Function (Phase 1)

Genetic Diseases, Inborn (Phase 3)

Infections (Phase 2)

Renal Insufficiency (Phase 1)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 6